Loading organizations...
§ Private Profile · New York City, NY, USA
Digital therapeutics developer creating diabetes prevention programs for prediabetic individuals, focused on type 2 diabetes.
Based in New York City, New York, Blue Mesa Health develops digital therapeutics and behavioral lifestyle interventions focused primarily on chronic disease prevention. The company provides CDC-recognized, 12-month diabetes prevention programs, specifically its flagship Transform and Transformemos platforms, which combine an evidence-based curriculum, connected hardware, software, and dedicated health coaches to delay type 2 diabetes onset. Operating on a business-to-business enterprise model with paid plans starting at $188 per month, the firm partners with health insurers, employee benefits providers, and corporate employers to deliver these interventions globally in both English and Spanish. Prior to its January 2020 acquisition by Virgin Pulse, the enterprise raised at least $750,000 in seed funding from a syndicate of institutional investors including Blueprint Health, Stanley Park Ventures, and Pallasite Ventures. Blue Mesa Health was originally founded in 2015 by Curtis Duggan.
Blue Mesa Health has raised $1.7M across 2 funding rounds.
Blue Mesa Health has raised $1.7M in total across 2 funding rounds.
Blue Mesa Health is a health technology company that develops digital therapeutics, primarily the Transform program—a CDC-recognized, evidence-based diabetes prevention initiative combining science, data, and design to deliver remote behavioral interventions for weight loss and chronic disease prevention[1][2][3][4]. It serves individuals, employers, and health plans by providing fully digital, multilingual programs (in languages like English, Spanish, Chinese, Portuguese, and Arabic) accessible across literacy levels and cultures, impacting over 10,000 participants globally with features like personalized coaching, mobile apps, peer support, and integration with health tracking devices such as smart scales[1][2][3]. The program achieves clinically meaningful outcomes, like 5% weight loss for pre-diabetics, through a 12-month curriculum priced at $188 for the first month (including devices) and $39 thereafter, generating revenue via subscriptions and partnerships[2][3].
Founded in 2015 in New York, Blue Mesa Health emerged to tackle the rising need for scalable type 2 diabetes prevention amid growing chronic disease burdens, focusing on digital platforms for evidence-based interventions like the CDC's Diabetes Prevention Program (DPP)[2][4]. Led by CEO Curtis Duggan, the company quickly gained traction with its Transform program, earning full CDC recognition for its effectiveness in reducing diabetes risk through lifestyle changes[1][4][7]. Key milestones include early development of remote monitoring and coaching tools, expansion to diverse global populations, and a pivotal 2020 acquisition by Virgin Pulse (itself later merged with other entities under Marlin Equity), which integrated Transform into Virgin Pulse's platform for broader reach to over six million members[4][7].
Blue Mesa Health rides the digital therapeutics wave in preventive health tech, capitalizing on post-pandemic demand for remote, scalable chronic disease management amid rising diabetes prevalence (affecting millions globally)[1][2][7]. Its timing aligns with employer/health plan shifts toward cost-saving interventions—DPPs can avert expensive treatments—fueled by CDC endorsements and integrations with wearables/AI-driven coaching[3][4][7]. By influencing ecosystems through Virgin Pulse's vast user base, it accelerates adoption of behavior-change tech, bridging consumer apps with enterprise wellness, and sets benchmarks for multilingual, evidence-driven tools in a $100B+ digital health market[3][7].
Post-2020 acquisition, Blue Mesa's Transform thrives within Virgin Pulse's ecosystem, poised for expansion via AI-enhanced personalization, broader device integrations, and global scaling to new markets/languages. Rising trends like value-based care and wearable data proliferation will amplify its impact, potentially evolving into full-spectrum chronic care platforms. As digital therapeutics mature, Blue Mesa exemplifies how science-backed tech optimizes health at scale—reinforcing its mission to prevent chronic diseases worldwide through accessible, data-driven design[1][7].
Blue Mesa Health has raised $1.7M in total across 2 funding rounds.
Blue Mesa Health's investors include N49P Ventures, Panache Ventures, Pioneer Square Labs, Radical Ventures, Dr. John R. Patrick, Blueprint Health, Mobio Technologies, Pallasite Ventures, Redbrick Media, Stanley Park Ventures.
Blue Mesa Health has raised $1.7M across 2 funding rounds. Most recently, it raised $970K Seed in February 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2018 | $970K Seed | — | N49p Ventures, Panache Ventures, Pioneer Square Labs, Radical Ventures | Announced |
| Jun 7, 2017 | $750K Seed | — | DR. John R. Patrick, Blueprint Health, Mobio Technologies, Pallasite Ventures, Redbrick Media, Stanley Park Ventures | Announced |